Relatives of Bladder Cancer Victims Who Took the Diabetes Drug Actos May Have Valuable Claims, Says Attorney Michael J. Evans

“Family members of bladder cancer victims who took the diabetes drug Actos may have valuable legal claims of their own,” says experienced drug litigation attorney Michael J. Evans. Evans says that even though many people have filed lawsuits allegi

ng that the diabetes drug Actos caused bladder cancer, he believes many more people have valuable claims that have not been filed.

Actos Lawsuit Website

That’s why Evans has launched a new Actos Lawsuit website and 24-hour toll-free phone service. Actos patients who developed bladder cancer as well as their family members are welcome to use the Free Actos Lawsuit Review Form, or call the Actos Helpline at 800-671-0996. The phone service is available 24 hours a day, 7 days a week.

Both the Actos Lawsuit website and the 24-hour Actos Helpline are available to people nationwide. Evans is working with a group of attorneys who are involved in Actos lawsuits already filed in

federal and state courts. Evans says his goal is to simplify the legal process for bladder cancer victims and their families.

“Some bladder cancer patients are too sick, or have died, and can’t file a lawsuit on their own behalf. But drug makers can’t avoid paying valid claims just because their drugs killed patients or made them too sick to file a lawsuit. Family members can usually act on the bladder cancer victim, and the family member may also have the right to collect money in addition to money collected by the bladder cancer victim (or the estate of the bladder cancer victim). For example, some states allow the recovery of money by spouses, and some allow the recovery by both spouses and children. It’s important for the family members of bladder cancer victims to understand their own rights, as well as the rights of the bladder cancer victim,” Evans said.

Evans says he believes visitors to the website will be especially interested in reading a page containing excerpts from a whistleblower lawsuit filed by Dr. Helen Ge, who was a medical researcher for the maker of Actos during clinical trials before the drug was approved by the FDA.

Dr. Ge’s entire 116-page lawsuit can be downloaded from the Actos Lawsuit website. Dr. Ge’s lawsuit is U.S. ex rel. Helen Ge v. Takeda Pharmaceutical Co., 10-cv-11043, U.S. District Court, District of Massachusetts (Boston). [Continue reading…]

Actos Bladder Cancer Risk Shown in May 31, 2012 Study

Actos bladder cancer risks shown in May 31, 2012 study, establishes Actos bladder cancer risk.

Actos, the trade name for the diabetes drug Pioglitazone, is associated with an increased risk of bladder cancer, finds a study pub

lished on today.

The results show that more than two years daily exposure to pioglitazone doubles the risk of Actos bladder cancer.

Actos bladder cancer risks were evaluated in a new study reported in on May 31, 2012. The study confirms previous studies

showing an Actos bladder cancer risk. According to an excerpt from the article, the Actos bladder cancer risk is clearly established:

Use of the anti-diabetic agent pioglitazone (Actos) is associated with an increased risk of bladder cancer, a nested case-control study confirmed.

Patients with type 2 diabetes who were ever treated with pioglitazone [Actos] had an 83% higher risk for bladder cancer (adjusted rate ratio 1.83, 95% CI 1.10 to 3.05) than those who had never used the thiazolidinedione, according to Laurent Azoulay, PhD, of McGill University in Montreal, and colleagues.

This was a drug-specific effect, because patients taking rosiglitazone (Avandia) did not have an elevated risk (RR 1.14, 95% CI 0.78 to 1.68), the

researchers reported online in


The results of this analysis differed from those of a study being presented this week at the annual meeting of the American Society of Clinical Oncology, which suggested that the bladder cancer risk was a class effect for glitazones.

Other previous efforts to ascertain if pioglitazone [Actos] is associated with bladder cancer have had conflicting results, but the FDA and the Canadian health authorities have added a warning of that risk to the drug’s labeling, and some European countries have restricted its use.

(Emphasis added)

In other articles published today about the study, ScienceCodex reported that the new study shows that 2 years of treatment with Actos doubles the risk of bladder cancer.

(Emphasis added).

Actos Bladder Cancer Resources May 31, 2012: